Michael D Huband - JoVE Visualize

Showing results (21-30 of 86) with videos related to

Pageof 9

Sort By:

International Journal of Antimicrobial Agents|March 7, 2018

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programmeMichael A Pfaller, Michael D Huband, Rodrigo E Mendes, et al.

International Journal of Antimicrobial Agents|October 9, 2014

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classesJohn Dallow, Linda G Otterson, Michael D Huband, et al.

Journal of Clinical Microbiology|August 11, 2017

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation CephalosporinStefan Riedel, Michael D Huband, Helio S Sader, et al.

Journal of Fungi (Basel, Switzerland)|February 25, 2023

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-PacificCecilia G Carvalhaes, Paul R Rhomberg, Michael D Huband, et al.

Journal of Global Antimicrobial Resistance|May 29, 2021

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)Michael A Pfaller, Michael D Huband, Robert K Flamm, et al.

Diagnostic Microbiology and Infectious Disease|May 8, 2020

Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanismsRodrigo E Mendes, Michael D Huband, Jennifer M Streit, et al.

Journal of Global Antimicrobial Resistance|June 24, 2025

In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023Steven I Aronin, Michael D Huband, Holly Becker, et al.

Surgical Infections|April 23, 2016

Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014Helio S Sader, Mariana Castanheira, Robert K Flamm, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 22, 2023

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)Helio S Sader, Cecilia G Carvalhaes, Michael D Huband, et al.

Journal of Clinical Microbiology|July 3, 2023

Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor CombinationMichael D Huband, Kelley A Fedler, Helio S Sader, et al.

Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:

Pageof 9

International Journal of Antimicrobial Agents|March 7, 2018

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programmeMichael A Pfaller, Michael D Huband, Rodrigo E Mendes, et al.

International Journal of Antimicrobial Agents|October 9, 2014

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classesJohn Dallow, Linda G Otterson, Michael D Huband, et al.

Journal of Clinical Microbiology|August 11, 2017

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation CephalosporinStefan Riedel, Michael D Huband, Helio S Sader, et al.

Journal of Fungi (Basel, Switzerland)|February 25, 2023

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-PacificCecilia G Carvalhaes, Paul R Rhomberg, Michael D Huband, et al.

Journal of Global Antimicrobial Resistance|May 29, 2021

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)Michael A Pfaller, Michael D Huband, Robert K Flamm, et al.

Diagnostic Microbiology and Infectious Disease|May 8, 2020

Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanismsRodrigo E Mendes, Michael D Huband, Jennifer M Streit, et al.

Journal of Global Antimicrobial Resistance|June 24, 2025

In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023Steven I Aronin, Michael D Huband, Holly Becker, et al.

Surgical Infections|April 23, 2016

Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014Helio S Sader, Mariana Castanheira, Robert K Flamm, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 22, 2023

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)Helio S Sader, Cecilia G Carvalhaes, Michael D Huband, et al.

Journal of Clinical Microbiology|July 3, 2023

Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor CombinationMichael D Huband, Kelley A Fedler, Helio S Sader, et al.

Pageof 9